GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (FRA:1UC) » Definitions » ROE % Adjusted to Book Value

Cue Biopharma (FRA:1UC) ROE % Adjusted to Book Value : -98.89% (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cue Biopharma ROE % Adjusted to Book Value?

Cue Biopharma's ROE % for the quarter that ended in Sep. 2024 was -145.37%. Cue Biopharma's PB Ratio for the quarter that ended in Sep. 2024 was 1.47. Cue Biopharma's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -98.89%.


Cue Biopharma ROE % Adjusted to Book Value Historical Data

The historical data trend for Cue Biopharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma ROE % Adjusted to Book Value Chart

Cue Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only -14.17 -13.86 -11.51 -45.10 -27.69

Cue Biopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.18 -38.06 -49.30 -50.77 -98.89

Competitive Comparison of Cue Biopharma's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Cue Biopharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cue Biopharma's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's ROE % Adjusted to Book Value falls into.


;
;

Cue Biopharma ROE % Adjusted to Book Value Calculation

Cue Biopharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-96.91% / 3.50
=-27.69%

Cue Biopharma's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-145.37% / 1.47
=-98.89%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cue Biopharma ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Cue Biopharma's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Cue Biopharma Business Description

Industry
Traded in Other Exchanges
Address
40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Cue Biopharma Headlines

No Headlines